Ranbaxy: Positive news flow - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy: Positive news flow

Jun 14, 2002

Ranbaxy has emerged a second time winner in terms of the anti-infective drug, ‘Cefuroxime Axetil’. Glaxo has obtained an injunction from a Chicago court against Apotex, the generic competitor of Ranbaxy to sell generic version of Ceftin in the US market. Now this comes as a big opportunity in disguise for Ranbaxy. The injunction obtained by Glaxo would mean that Apotex would not be able to launch the drug in US, unless it can vacate the injunction. However, the next hearing on the case is expected only in Dec’ 02 and hence in the meantime Ranbaxy can continue with its ‘technical’ monopoly status on the drug.

To put things in perspective, it may be recalled that Ranbaxy received FDA approval for marketing Cefuroxime Axetil tablets in the US markets after a prolonged legal battle with Glaxo, the original patent holder on the US$ 400 m drug, Ceftin (generic Cefuroxime). The approval didn’t ensure any marketing exclusivity for Ranbaxy. However, due to lack of any other player in the market with necessary approvals, Ranbaxy enjoys ‘technical’ monopoly (in generic version) for marketing the drug. The company received approval for Cefuroxime in Feb'02 and has already enjoyed almost 5 months of exclusivity on the drug. Apotex is the only generic competitor for Ranbaxy and was expected to launch the drug, late this month. However, with Glaxo obtaining injunction against Apotex, Ranbaxy would continue with its monopoly status.

Now let’s analyze the worst and best case scenario for Ranbaxy. Apart from the injunction, Apotex also has to clear a patent infringement case filed by GSK. Glaxo claims that the company infringes certain patents (on the amorphous form), which expire in July’03. To Ranbaxy’s advantage if Apotex doesn’t win the case, it could enjoy monopoly status till July’03 (i.e. 18 months!). Even in the worst case, it seems that the company would continue with its monopoly status till Dec’ 02.

Earlier we had expected entry of Apotex by July’02. Based on that we had targeted a revenue potential of US$ 48 m for Ranbaxy from this. However, in this new scenario the revenues from this generic in the current year (FY03-Dec’02) could well touch US$ 90 m. The contribution to the bottom line from this incremental sales is expected to be huge considering the margins of the company here are anywhere in the range of 70-80%. Consequently, we would be revising our earnings estimates soon.

Equitymaster requests your view! Post a comment on "Ranbaxy: Positive news flow". Click here!

  

More Views on News

Sorry! There are no related views on news for this company/sector.

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On... (Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday (Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS